Back To Rising Leaders Gallery
In this installment of In Vivo’s 2021 Rising Leaders series, we hear from Nazli Azimi, founder and CEO of
California-based Bioniz’s lead candidate for cutaneous T-cell lymphoma has been granted orphan drug designation and expects to begin Phase III trials in the second half of 2021. CEO Nazli Azimi explains the science, which originated from her research in academia, and talks about her entrepreneurial journey.
Back To Rising Leaders Gallery
In this installment of In Vivo’s 2021 Rising Leaders series, we hear from Nazli Azimi, founder and CEO of